Results 221 to 230 of about 328,983 (310)

Beyond CD30: Dual‐Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides

open access: yesAdvanced Science, EarlyView.
Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Yi Jiang   +8 more
wiley   +1 more source

Discovery of an Adaptive Neuroimmune Response Driving Itch and Fast Tick Removal with Implications for Preventing Pathogen Transmission

open access: yesAdvanced Science, EarlyView.
Doehl et al. discovered an adaptive neuroimmune mechanism that induces itch in tick‐exposed guinea pigs, enabling rapid tick removal. This itch‐induced tick removal (IITR) is mediated by an adaptive cellular immune response and is independent of IgG, IgE, or TRPV1.
Johannes S. P. Doehl   +27 more
wiley   +1 more source

Synergistic Mn‐MOF Activation of Pistol Ribozymes for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
A Mn2+‐based metal–organic framework delivers a catalytic Pistol ribozyme for targeted PD‐L1 mRNA cleavage in tumor cells, with the released Mn2+ not only inducing immune activation in immune cells but also increasing the Pistol ribozyme catalytic activity.
Ming Zhao   +10 more
wiley   +1 more source

Distinct Immunomodulatory Strategies Guide Mesenchymal Stromal/Stem Cell‐Mediated Bone Regeneration

open access: yesAdvanced Science, EarlyView.
Bone regeneration by mesenchymal stem cells is strongly influenced by immune signals. This study shows that priming stem cells with regulatory immune cells or an inflammation‐resolving lipid molecule enhances bone formation through distinct immune pathways.
Salwa Suliman   +5 more
wiley   +1 more source

NK Cell Activation by Platinum Boosts Immunotherapy in HR+/HER2− Breast Cancer

open access: yesAdvanced Science, EarlyView.
Multi‐omics and single‐cell analyses identify activated NK cells as key mediators of anti‐PD‐(L)1 response in HR+/HER2− breast cancer. Platinum chemotherapy enhances NK cell cytotoxicity through NF‐κB–associated signaling, synergizing with immunotherapy and providing a rationale for combination treatment.
Yi‐Yu Chen   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy